Why Adult Suicide-Risk Screening Received an I Statement

In June 2023, the U.S. Preventive Services Task Force concluded that evidence was insufficient to assess the benefits and harms of screening adults for suicide risk. This is an I statement. It covers adults, including pregnant and postpartum people and adults age 65 or older, who do not have a diagnosed mental health disorder and do not have recognized signs or symptoms of depression or suicide risk.

The same recommendation gives depression screening a B grade. The contrast can look contradictory because suicidal thinking can occur with depression. The Task Force evaluated two distinct preventive services with different evidence chains. Depression-screening programs had evidence that linked detection to evaluation and treatment. Suicide-risk screening lacked enough evidence on test accuracy in relevant settings, downstream interventions, health outcomes, and harms to estimate net benefit.

An I statement is not a recommendation against asking about suicide. It does not apply to you if you report thoughts of death, show concerning symptoms, have had a recent attempt, present after self-harm, or otherwise prompt clinical concern. Those situations require assessment and care, not population screening logic.

What preventive screening means#

Screening offers a test or questionnaire to people who have not sought care for symptoms and are not already identified as having the condition of interest. Its purpose is to find otherwise unrecognized cases early enough that a beneficial intervention changes outcomes.

That definition is narrower than clinical assessment. If a patient says, "I do not want to be alive," asking about suicidal thoughts, intent, plan, access to lethal means, prior behavior, and immediate safety is not universal screening. It is an indicated response to a symptom. The distinction matters because evidence from symptomatic emergency or psychiatric populations cannot automatically establish the value of screening every asymptomatic adult in primary care. Prevalence, urgency, available staff, follow-up, and the meaning of a positive response differ.

What the letter I means#

The USPSTF uses I when evidence is lacking, poor quality, conflicting, or unable to determine the balance of benefits and harms. It is not part of the A-to-D ranking from strongly offer to discourage. It marks an unresolved evidence question.

For an I statement, clinicians use judgment and consider the Task Force's suggestions for practice. Researchers are given a map of the missing studies. Health systems should not convert the letter into either "screen everyone" or "never ask." The absence of a population recommendation also does not prevent organizations from adopting policies based on other standards, local resources, or emerging evidence. It means those policies should not be described as having a settled USPSTF net-benefit determination.

The evidence chain a screening program needs#

A screening program can help only if several links hold. The instrument must identify relevant risk with acceptable accuracy in the population where it will be used. Positive results must lead to a timely, valid assessment. Effective interventions must be available and accepted. Follow-up must occur. The combined pathway must reduce attempts, deaths, severe distress, or another patient-important outcome more than it causes harm.

Research that validates a questionnaire against another interview addresses one link. A treatment trial among patients already receiving psychiatric care addresses another. Neither alone proves that universal screening in primary care improves population outcomes. The Task Force sought direct evidence comparing screened and unscreened groups as well as indirect evidence for each link. It found too little to estimate the full balance for suicide-risk screening in adults.

Why accuracy is difficult to establish#

Suicide death and attempts are uncommon relative to the number of people who may endorse a screening item. Even an instrument with useful sensitivity and specificity can produce many false-positive classifications when the outcome is rare. Risk also changes over time, and a short questionnaire cannot capture every transition.

Different studies used different tools, thresholds, settings, and outcomes. Some measured thoughts, some attempts, and some combined events. A question that detects current suicidal ideation is not the same as a model that predicts a future attempt or death.

A positive response can still be clinically important even when it does not predict a rare event. It may identify current distress or an unmet need. That supports follow-up assessment; it does not prove the net benefit of offering the screen to every asymptomatic adult.

Why outcome evidence matters beyond finding more people#

Screening often increases identification. Identification is an intermediate outcome. The preventive goal is better health and safety.

To demonstrate benefit, a study could randomize clinics or patients to a screening program versus usual care, ensure appropriate evaluation and intervention, and measure attempts, symptoms, functioning, quality of life, service use, and deaths over sufficient follow-up. It would need enough participants because suicide is rare.

If your system screens without capacity for same-day assessment, safety planning, treatment, and follow-up, detection may not translate into benefit. The Task Force emphasizes that screening programs require adequate systems to diagnose, treat, and monitor. A question is not a care pathway.

Potential harms also need measurement#

Asking about suicide does not appear to create suicidal thoughts merely by asking, a common fear not supported by available research. Harms can arise elsewhere in the pathway: false reassurance after a negative screen, stigma, breach of privacy, coercive responses that are not proportionate to need, emergency referral without continuity, or inequitable interpretation.

False positives can consume scarce services or subject a person to distressing evaluation. False negatives can leave a clinician or a system believing your risk has been ruled out. Poorly explained questions may reduce trust. Documentation can follow a person across settings. These concerns do not prove that screening's harms outweigh benefits. They are reasons the net balance must be studied and why implementation quality matters.

Why depression screening received a B grade#

The USPSTF recommends depression screening in adults, including pregnant and postpartum people and older adults, when systems exist for diagnosis, treatment, and follow-up. Depression is more common than suicide death, validated screening tools are available, and treatment evidence supports the pathway from identification to improved depression outcomes.

Depression screening may include an item about thoughts of death or self-harm. A positive response requires immediate attention. Still, evidence for a depression-screening program does not answer whether a separate universal suicide-risk instrument improves suicide outcomes in everyone. The two grades can coexist because the target conditions, endpoints, prevalence, tools, and intervention chains all differ.

The recommendation does not cover people with concern#

Anyone with recognized symptoms, current distress, known mental illness, a history of suicidal behavior, recent self-harm, major acute loss, intoxication, agitation, psychosis, or another concerning presentation is outside the asymptomatic screening population, and clinical assessment should then be guided by your need and its urgency.

Assessment is broader than a score. It can include current thoughts, intent, planning, access to lethal means, prior attempts, recent changes, substance use, mental state, pain, medical illness, supports, reasons for living, and ability to participate in a safety plan. The purpose is to understand needs and create a proportionate plan, not to predict the future with certainty.

A person can deny current thoughts and still require care based on behavior, collateral information, or other findings. A positive screen can occur without imminent intent. The next assessment is essential in both cases.

What better research would look like#

The USPSTF called for studies in primary-care populations that reflect age, pregnancy and postpartum status, race and ethnicity, sex and gender, rural and urban settings, and people facing barriers to care. Instruments need consistent outcomes and thresholds.

Trials should test complete programs, not isolated questions. They should report both benefits and harms, the response to positive results, follow-up completion, and patient-centered outcomes. They should distinguish suicidal ideation, attempts, self-harm without suicidal intent, and suicide death. Because service availability changes the effect of screening, studies should describe staffing, referral access, crisis response, privacy, and continuity. A program's success in a well-resourced research clinic may not transfer to a setting without those supports.

Immediate safety is not an evidence-literacy exercise#

If someone may act on suicidal thoughts now, has a plan or intent, has recently attempted suicide, cannot maintain safety, or poses immediate danger, call emergency services or go to an emergency department. Do not leave a person at imminent risk alone. A trusted person can help reduce access to firearms, medications, or other lethal means while urgent help is arranged.

In the United States, call or text 988 to reach the Suicide & Crisis Lifeline. In an immediate life-threatening emergency, call 911. Outside the United States, use the local emergency number or crisis line. A screening grade should never delay urgent care.